Compare SATL & CDNA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | SATL | CDNA |
|---|---|---|
| Founded | 2010 | 1998 |
| Country | United States | United States |
| Employees | 154 | N/A |
| Industry | Radio And Television Broadcasting And Communications Equipment | Medical Specialities |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 968.5M | 1.0B |
| IPO Year | N/A | 2007 |
| Metric | SATL | CDNA |
|---|---|---|
| Price | $6.78 | $19.83 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 3 | 6 |
| Target Price | $5.50 | ★ $27.60 |
| AVG Volume (30 Days) | ★ 14.0M | 694.4K |
| Earning Date | 05-12-2026 | 04-28-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $48,324,000.00 |
| Revenue This Year | $88.89 | $16.01 |
| Revenue Next Year | $56.98 | $11.31 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 18.93 |
| 52 Week Low | $1.26 | $10.96 |
| 52 Week High | $8.35 | $23.24 |
| Indicator | SATL | CDNA |
|---|---|---|
| Relative Strength Index (RSI) | 57.33 | 55.47 |
| Support Level | $6.49 | $16.63 |
| Resistance Level | $6.84 | $21.20 |
| Average True Range (ATR) | 0.87 | 1.30 |
| MACD | -0.13 | 0.34 |
| Stochastic Oscillator | 18.22 | 54.88 |
Satellogic Inc is a vertically integrated Earth observation company that designs, manufactures, and operates satellite systems, delivering decision-grade insights at scale to government and commercial customers. Through an end-to-end production and operations model, it provides governments with flexible options across their journey toward sovereign Earth observation. From access to high-frequency imagery and managed space systems to full satellite ownership, to supporting autonomous data availability and long-term technological independence. It has monitoring and alert-driven workflows that help defense and intelligence agencies, civil governments, and commercial operators transition from reactive tasking to proactive decision-making, providing mission-critical data when needed.
CareDx Inc operates as a precision medicine company focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers. It offers testing services, products, and digital solutions along with the pre- and post-transplant patient journey and is a provider of genomics-based information for transplant patients. The Company's commercially available testing services consist of AlloSure Kidney, AlloMap Heart, AlloSure Heart, a dd-cfDNA solution for heart transplant patients, and AlloSure Lung, a dd-cfDNA solution for lung transplant patients. Geographically the company generates the majority of its revenue from the United States. The company generates the majority of revenue from the Testing services.